| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| BCG Vaccine | 11 | 2021 | 1137 | 2.56 | Why? |
| Immunity, Heterologous | 4 | 2020 | 129 | 2.34 | Why? |
| Interferon-gamma Release Tests | 5 | 2019 | 253 | 1.72 | Why? |
| Mycobacterium Infections, Nontuberculous | 5 | 2020 | 167 | 1.63 | Why? |
| Latent Tuberculosis | 5 | 2019 | 324 | 1.37 | Why? |
| Vancomycin | 3 | 2019 | 328 | 1.35 | Why? |
| Neonatal Sepsis | 2 | 2018 | 69 | 1.34 | Why? |
| Tuberculosis | 7 | 2021 | 2895 | 1.29 | Why? |
| Osteomyelitis | 2 | 2018 | 131 | 1.26 | Why? |
| Streptococcal Infections | 3 | 2018 | 255 | 1.19 | Why? |
| Anti-Bacterial Agents | 11 | 2019 | 10083 | 1.14 | Why? |
| Meningitis, Bacterial | 2 | 2017 | 111 | 1.02 | Why? |
| Mucocutaneous Lymph Node Syndrome | 7 | 2020 | 1645 | 0.98 | Why? |
| Gastrointestinal Microbiome | 3 | 2019 | 1961 | 0.88 | Why? |
| Shock, Septic | 4 | 2018 | 1313 | 0.86 | Why? |
| Antigens, Bacterial | 3 | 2019 | 330 | 0.84 | Why? |
| Nontuberculous Mycobacteria | 3 | 2020 | 114 | 0.82 | Why? |
| Buruli Ulcer | 2 | 2020 | 17 | 0.81 | Why? |
| Haemophilus Vaccines | 2 | 2019 | 76 | 0.81 | Why? |
| Mycobacterium bovis | 1 | 2021 | 125 | 0.80 | Why? |
| Aspirin | 2 | 2018 | 1043 | 0.79 | Why? |
| Salicylic Acid | 1 | 2018 | 10 | 0.78 | Why? |
| Acquired Hyperostosis Syndrome | 1 | 2018 | 6 | 0.78 | Why? |
| Propionibacterium acnes | 1 | 2018 | 19 | 0.77 | Why? |
| Antigens, Heterophile | 1 | 2018 | 5 | 0.76 | Why? |
| Mycobacterium ulcerans | 1 | 2018 | 15 | 0.76 | Why? |
| Vaccines | 4 | 2018 | 3692 | 0.73 | Why? |
| Toll-Like Receptors | 2 | 2018 | 365 | 0.72 | Why? |
| Humerus | 1 | 2017 | 19 | 0.72 | Why? |
| Mycobacterium tuberculosis | 2 | 2018 | 1164 | 0.72 | Why? |
| Gram-Positive Bacteria | 1 | 2019 | 230 | 0.72 | Why? |
| Brachial Plexus Neuropathies | 1 | 2017 | 20 | 0.71 | Why? |
| Colony Count, Microbial | 1 | 2018 | 177 | 0.71 | Why? |
| Tetanus Toxoid | 1 | 2019 | 136 | 0.70 | Why? |
| Cytokines | 5 | 2020 | 15010 | 0.65 | Why? |
| Antipyretics | 1 | 2017 | 107 | 0.64 | Why? |
| Bone and Bones | 1 | 2018 | 235 | 0.62 | Why? |
| Streptococcus agalactiae | 1 | 2017 | 194 | 0.61 | Why? |
| Measles-Mumps-Rubella Vaccine | 1 | 2019 | 282 | 0.60 | Why? |
| Dermatologic Surgical Procedures | 1 | 2017 | 138 | 0.57 | Why? |
| Gram-Negative Bacteria | 1 | 2019 | 473 | 0.56 | Why? |
| Poliomyelitis | 1 | 2019 | 263 | 0.56 | Why? |
| Gram-Positive Bacterial Infections | 1 | 2018 | 323 | 0.56 | Why? |
| Food Hypersensitivity | 1 | 2019 | 397 | 0.52 | Why? |
| Infant | 21 | 2021 | 30274 | 0.52 | Why? |
| Drug Interactions | 2 | 2018 | 1653 | 0.50 | Why? |
| Intestines | 1 | 2018 | 817 | 0.47 | Why? |
| Communicable Diseases | 2 | 2017 | 2148 | 0.46 | Why? |
| Chemokine CXCL10 | 1 | 2015 | 565 | 0.44 | Why? |
| Probiotics | 1 | 2017 | 694 | 0.39 | Why? |
| Microbiota | 1 | 2019 | 1240 | 0.38 | Why? |
| Refugees | 1 | 2019 | 809 | 0.37 | Why? |
| Environmental Exposure | 1 | 2019 | 1558 | 0.37 | Why? |
| Catheter-Related Infections | 3 | 2018 | 381 | 0.36 | Why? |
| Child | 26 | 2021 | 70012 | 0.36 | Why? |
| Milk, Human | 1 | 2017 | 956 | 0.36 | Why? |
| Tuberculin Test | 2 | 2019 | 141 | 0.35 | Why? |
| Staphylococcal Infections | 1 | 2017 | 1099 | 0.34 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 1454 | 0.34 | Why? |
| Vaccines, Conjugate | 2 | 2019 | 328 | 0.32 | Why? |
| Vaccination | 8 | 2021 | 19050 | 0.32 | Why? |
| Infant, Newborn | 11 | 2020 | 23105 | 0.32 | Why? |
| Diphtheria | 2 | 2019 | 74 | 0.32 | Why? |
| Breast Feeding | 1 | 2017 | 1585 | 0.31 | Why? |
| Immunity, Innate | 3 | 2021 | 6570 | 0.31 | Why? |
| Drug Monitoring | 3 | 2019 | 1408 | 0.31 | Why? |
| Immunity, Humoral | 2 | 2018 | 4849 | 0.31 | Why? |
| Corynebacterium diphtheriae | 1 | 2005 | 19 | 0.30 | Why? |
| Urinary Tract Infections | 1 | 2011 | 534 | 0.29 | Why? |
| Anti-Infective Agents | 1 | 2017 | 1766 | 0.29 | Why? |
| CD4-Positive T-Lymphocytes | 2 | 2020 | 4545 | 0.28 | Why? |
| Infusions, Intravenous | 2 | 2019 | 1224 | 0.27 | Why? |
| Humans | 65 | 2021 | 930598 | 0.27 | Why? |
| Skin Diseases, Bacterial | 1 | 2005 | 105 | 0.27 | Why? |
| Skin Ulcer | 1 | 2005 | 98 | 0.27 | Why? |
| Fever | 2 | 2020 | 7795 | 0.26 | Why? |
| Infectious Disease Transmission, Vertical | 2 | 2020 | 5164 | 0.26 | Why? |
| Retina | 2 | 2018 | 424 | 0.25 | Why? |
| Disease Management | 3 | 2017 | 6841 | 0.25 | Why? |
| Coronary Artery Disease | 1 | 2017 | 2570 | 0.24 | Why? |
| Immunoglobulins, Intravenous | 3 | 2020 | 2705 | 0.24 | Why? |
| Carotid Intima-Media Thickness | 3 | 2018 | 179 | 0.24 | Why? |
| Child, Preschool | 12 | 2021 | 36283 | 0.23 | Why? |
| Ethanol | 3 | 2018 | 533 | 0.23 | Why? |
| Biomarkers | 3 | 2019 | 23361 | 0.22 | Why? |
| Nucleic Acid Synthesis Inhibitors | 1 | 2020 | 43 | 0.21 | Why? |
| Immunomodulation | 2 | 2020 | 1472 | 0.21 | Why? |
| Fetal Distress | 1 | 2020 | 70 | 0.20 | Why? |
| Infant Mortality | 2 | 2020 | 268 | 0.20 | Why? |
| Milk Proteins | 1 | 2019 | 47 | 0.20 | Why? |
| Pertussis Toxin | 1 | 2019 | 19 | 0.20 | Why? |
| Tuberculosis Vaccines | 1 | 2020 | 89 | 0.20 | Why? |
| Pulse Wave Analysis | 2 | 2018 | 221 | 0.20 | Why? |
| T-Cell Antigen Receptor Specificity | 1 | 2019 | 93 | 0.20 | Why? |
| Mycobacterium abscessus | 1 | 2019 | 31 | 0.19 | Why? |
| Adolescent | 17 | 2021 | 86841 | 0.19 | Why? |
| Polysaccharides, Bacterial | 1 | 2019 | 59 | 0.19 | Why? |
| Clindamycin | 1 | 2018 | 59 | 0.19 | Why? |
| Australia | 6 | 2020 | 6306 | 0.19 | Why? |
| Antibodies, Bacterial | 2 | 2019 | 510 | 0.18 | Why? |
| Chemokine CCL4 | 1 | 2018 | 71 | 0.18 | Why? |
| Chemokine CCL3 | 1 | 2018 | 103 | 0.18 | Why? |
| Drug Dosage Calculations | 1 | 2019 | 243 | 0.18 | Why? |
| Cross Protection | 1 | 2020 | 373 | 0.18 | Why? |
| Injections, Intravenous | 1 | 2019 | 381 | 0.17 | Why? |
| Ethambutol | 1 | 2017 | 34 | 0.17 | Why? |
| Epidemics | 1 | 2018 | 6407 | 0.17 | Why? |
| Male | 27 | 2020 | 367725 | 0.17 | Why? |
| Laboratory Proficiency Testing | 1 | 2018 | 85 | 0.17 | Why? |
| Drug Stability | 1 | 2018 | 236 | 0.17 | Why? |
| Female | 26 | 2020 | 380317 | 0.17 | Why? |
| Range of Motion, Articular | 1 | 2017 | 168 | 0.17 | Why? |
| New South Wales | 1 | 2018 | 336 | 0.16 | Why? |
| Toll-Like Receptor 2 | 1 | 2018 | 198 | 0.16 | Why? |
| Bacteremia | 3 | 2018 | 1372 | 0.16 | Why? |
| Proof of Concept Study | 1 | 2019 | 696 | 0.16 | Why? |
| Food | 1 | 2019 | 316 | 0.16 | Why? |
| Clarithromycin | 1 | 2017 | 112 | 0.16 | Why? |
| Biofilms | 2 | 2017 | 304 | 0.16 | Why? |
| Immunologic Tests | 1 | 2019 | 445 | 0.16 | Why? |
| Biological Transport | 1 | 2017 | 290 | 0.15 | Why? |
| Diagnosis, Differential | 3 | 2020 | 7220 | 0.15 | Why? |
| Chemokine CCL2 | 1 | 2018 | 389 | 0.15 | Why? |
| Pharyngitis | 1 | 2020 | 687 | 0.15 | Why? |
| Blood Culture | 1 | 2018 | 308 | 0.15 | Why? |
| Young Adult | 14 | 2021 | 93724 | 0.15 | Why? |
| Observer Variation | 1 | 2018 | 622 | 0.15 | Why? |
| Immunocompetence | 1 | 2017 | 280 | 0.15 | Why? |
| Hydrophobic and Hydrophilic Interactions | 1 | 2017 | 382 | 0.15 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2020 | 10649 | 0.15 | Why? |
| Feces | 2 | 2020 | 4235 | 0.15 | Why? |
| Antibody Formation | 2 | 2019 | 4038 | 0.14 | Why? |
| Rifampin | 1 | 2017 | 276 | 0.14 | Why? |
| Case-Control Studies | 6 | 2018 | 17671 | 0.14 | Why? |
| RNA, Ribosomal, 16S | 1 | 2018 | 793 | 0.14 | Why? |
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2015 | 170 | 0.14 | Why? |
| Russia | 1 | 2019 | 989 | 0.14 | Why? |
| Macrolides | 1 | 2018 | 369 | 0.14 | Why? |
| Aorta, Thoracic | 1 | 2017 | 271 | 0.14 | Why? |
| Placebos | 1 | 2017 | 629 | 0.14 | Why? |
| Saliva | 2 | 2021 | 4679 | 0.14 | Why? |
| Microbial Viability | 1 | 2018 | 406 | 0.14 | Why? |
| Virulence Factors | 1 | 2017 | 338 | 0.14 | Why? |
| Developed Countries | 1 | 2018 | 500 | 0.14 | Why? |
| Immunophenotyping | 1 | 2019 | 1290 | 0.13 | Why? |
| Influenza Vaccines | 1 | 2010 | 2941 | 0.13 | Why? |
| Microvessels | 1 | 2018 | 490 | 0.13 | Why? |
| Retinal Vessels | 1 | 2017 | 255 | 0.13 | Why? |
| Face | 1 | 2017 | 301 | 0.13 | Why? |
| Vaccines, DNA | 1 | 2020 | 871 | 0.13 | Why? |
| Pneumocystis carinii | 1 | 2015 | 205 | 0.13 | Why? |
| Ligands | 1 | 2018 | 1300 | 0.12 | Why? |
| Allergens | 1 | 2019 | 728 | 0.12 | Why? |
| Immunization, Secondary | 1 | 2021 | 1649 | 0.12 | Why? |
| Infliximab | 1 | 2017 | 502 | 0.12 | Why? |
| Cytomegalovirus | 1 | 2017 | 600 | 0.12 | Why? |
| Immunization | 2 | 2019 | 2019 | 0.12 | Why? |
| Educational Status | 1 | 2018 | 1451 | 0.12 | Why? |
| Attitude of Health Personnel | 1 | 2010 | 4741 | 0.12 | Why? |
| Catheterization, Central Venous | 2 | 2018 | 458 | 0.12 | Why? |
| Anti-Infective Agents, Local | 1 | 2018 | 520 | 0.11 | Why? |
| Inflammasomes | 1 | 2018 | 710 | 0.11 | Why? |
| Interleukin-10 | 1 | 2018 | 1409 | 0.11 | Why? |
| Cytomegalovirus Infections | 1 | 2017 | 667 | 0.11 | Why? |
| Spinal Puncture | 1 | 2011 | 95 | 0.11 | Why? |
| Pneumonia, Pneumocystis | 1 | 2015 | 322 | 0.11 | Why? |
| Immunization Schedule | 1 | 2018 | 1305 | 0.11 | Why? |
| Adjuvants, Immunologic | 1 | 2020 | 1709 | 0.11 | Why? |
| Risk Assessment | 4 | 2018 | 25439 | 0.10 | Why? |
| Antitubercular Agents | 1 | 2017 | 775 | 0.10 | Why? |
| Flow Cytometry | 1 | 2019 | 2393 | 0.10 | Why? |
| Adult | 14 | 2021 | 244371 | 0.10 | Why? |
| Bacterial Proteins | 1 | 2019 | 1318 | 0.10 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.10 | Why? |
| HIV Infections | 1 | 2015 | 11620 | 0.10 | Why? |
| Lymphocyte Activation | 1 | 2019 | 2742 | 0.09 | Why? |
| Cystic Fibrosis | 1 | 2019 | 1104 | 0.09 | Why? |
| Opportunistic Infections | 1 | 2015 | 602 | 0.09 | Why? |
| Diagnostic Tests, Routine | 2 | 2017 | 2643 | 0.09 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.09 | Why? |
| Emergency Medicine | 1 | 2018 | 936 | 0.09 | Why? |
| Research Personnel | 1 | 2018 | 1037 | 0.09 | Why? |
| Premature Birth | 1 | 2020 | 2151 | 0.09 | Why? |
| Kidney Diseases | 1 | 2019 | 1434 | 0.09 | Why? |
| Platelet Aggregation Inhibitors | 1 | 2018 | 1671 | 0.09 | Why? |
| Catheters, Indwelling | 2 | 2018 | 84 | 0.09 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.09 | Why? |
| Cells, Cultured | 1 | 2019 | 5835 | 0.09 | Why? |
| Bacteria | 1 | 2018 | 1897 | 0.08 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 8811 | 0.08 | Why? |
| Hospitals, Pediatric | 1 | 2018 | 1792 | 0.08 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.08 | Why? |
| SARS Virus | 2 | 2020 | 13021 | 0.08 | Why? |
| Cough | 1 | 2020 | 4891 | 0.08 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.08 | Why? |
| Cardiovascular Diseases | 4 | 2018 | 11497 | 0.07 | Why? |
| Influenza, Human | 1 | 2010 | 10779 | 0.07 | Why? |
| Seasons | 1 | 2018 | 4071 | 0.07 | Why? |
| Skin | 1 | 2017 | 2096 | 0.07 | Why? |
| Time Factors | 2 | 2018 | 31397 | 0.07 | Why? |
| Reproducibility of Results | 2 | 2018 | 11304 | 0.07 | Why? |
| Incidence | 4 | 2020 | 25622 | 0.07 | Why? |
| Cohort Studies | 2 | 2019 | 36005 | 0.07 | Why? |
| Protease Inhibitors | 1 | 2020 | 3630 | 0.07 | Why? |
| Middle Aged | 8 | 2021 | 270681 | 0.06 | Why? |
| Seroepidemiologic Studies | 1 | 2019 | 10017 | 0.06 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.06 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.06 | Why? |
| Myocarditis | 1 | 2018 | 2731 | 0.06 | Why? |
| Developing Countries | 1 | 2018 | 4283 | 0.06 | Why? |
| Animals | 4 | 2020 | 78931 | 0.06 | Why? |
| Sepsis | 1 | 2019 | 3517 | 0.06 | Why? |
| Evidence-Based Medicine | 2 | 2015 | 3228 | 0.06 | Why? |
| Antirheumatic Agents | 1 | 2017 | 3023 | 0.06 | Why? |
| Immunologic Factors | 1 | 2018 | 4206 | 0.06 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 2 | 2020 | 8843 | 0.06 | Why? |
| India | 1 | 2019 | 11875 | 0.05 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.05 | Why? |
| Antibodies, Monoclonal | 1 | 2020 | 8041 | 0.05 | Why? |
| Tertiary Care Centers | 1 | 2018 | 8248 | 0.05 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.05 | Why? |
| Disease Progression | 1 | 2019 | 13580 | 0.05 | Why? |
| Interleukin-6 | 1 | 2018 | 7522 | 0.05 | Why? |
| Haemophilus influenzae type b | 1 | 2019 | 30 | 0.05 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.05 | Why? |
| Neoplasms | 2 | 2018 | 17251 | 0.05 | Why? |
| Severe Acute Respiratory Syndrome | 2 | 2020 | 12361 | 0.05 | Why? |
| Adrenal Cortex Hormones | 1 | 2017 | 6537 | 0.05 | Why? |
| Virus Replication | 2 | 2020 | 14331 | 0.05 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.05 | Why? |
| Poliovirus Vaccine, Inactivated | 1 | 2019 | 72 | 0.05 | Why? |
| Hematologic Neoplasms | 1 | 2012 | 2105 | 0.05 | Why? |
| Tetanus | 1 | 2019 | 61 | 0.05 | Why? |
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2019 | 92 | 0.05 | Why? |
| Infant, Extremely Premature | 1 | 2019 | 144 | 0.05 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.05 | Why? |
| Antiviral Agents | 2 | 2017 | 41703 | 0.05 | Why? |
| Leprosy | 1 | 2020 | 142 | 0.04 | Why? |
| Dose-Response Relationship, Drug | 2 | 2019 | 3776 | 0.04 | Why? |
| Streptococcus pyogenes | 1 | 2018 | 118 | 0.04 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.04 | Why? |
| Pregnancy | 1 | 2020 | 23879 | 0.04 | Why? |
| Disaster Planning | 1 | 2010 | 1680 | 0.04 | Why? |
| Carotid Artery, Common | 1 | 2017 | 49 | 0.04 | Why? |
| Double-Blind Method | 2 | 2018 | 5988 | 0.04 | Why? |
| Retrospective Studies | 5 | 2020 | 105322 | 0.04 | Why? |
| Whooping Cough | 1 | 2019 | 201 | 0.04 | Why? |
| Carotid Arteries | 1 | 2018 | 182 | 0.04 | Why? |
| Medical Records | 1 | 2019 | 513 | 0.04 | Why? |
| Brachial Artery | 1 | 2017 | 107 | 0.04 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.04 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 2984 | 0.04 | Why? |
| Aorta | 1 | 2018 | 355 | 0.04 | Why? |
| Administration, Intravenous | 1 | 2019 | 1115 | 0.04 | Why? |
| Research | 2 | 2018 | 2115 | 0.04 | Why? |
| Vascular Stiffness | 1 | 2018 | 264 | 0.04 | Why? |
| Interleukin-2 | 1 | 2017 | 443 | 0.04 | Why? |
| Aged | 4 | 2020 | 215776 | 0.04 | Why? |
| Victoria | 1 | 2017 | 607 | 0.03 | Why? |
| Eosinophils | 1 | 2021 | 848 | 0.03 | Why? |
| Gestational Age | 1 | 2019 | 1488 | 0.03 | Why? |
| Prospective Studies | 1 | 2019 | 43301 | 0.03 | Why? |
| Intensive Care Units, Neonatal | 1 | 2019 | 749 | 0.03 | Why? |
| Pneumococcal Vaccines | 1 | 2019 | 571 | 0.03 | Why? |
| Career Choice | 1 | 2018 | 498 | 0.03 | Why? |
| Secondary Prevention | 1 | 2018 | 762 | 0.03 | Why? |
| Antibiotic Prophylaxis | 1 | 2015 | 399 | 0.03 | Why? |
| Internet | 1 | 2010 | 6204 | 0.03 | Why? |
| Dendritic Cells | 1 | 2021 | 1330 | 0.03 | Why? |
| New Zealand | 1 | 2018 | 2073 | 0.03 | Why? |
| Measles | 1 | 2019 | 608 | 0.03 | Why? |
| Netherlands | 1 | 2020 | 3533 | 0.03 | Why? |
| Leukocytes, Mononuclear | 1 | 2021 | 2115 | 0.03 | Why? |
| Killer Cells, Natural | 1 | 2021 | 2093 | 0.03 | Why? |
| Hypersensitivity | 1 | 2020 | 1137 | 0.03 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.02 | Why? |
| Drug Administration Schedule | 1 | 2015 | 2324 | 0.02 | Why? |
| Immunologic Memory | 1 | 2020 | 3362 | 0.02 | Why? |
| Surveys and Questionnaires | 2 | 2018 | 43792 | 0.02 | Why? |
| Risk Factors | 4 | 2018 | 71621 | 0.02 | Why? |
| Monocytes | 1 | 2020 | 2978 | 0.02 | Why? |
| Temperature | 1 | 2018 | 2305 | 0.02 | Why? |
| Lymphopenia | 1 | 2020 | 2669 | 0.02 | Why? |
| Aged, 80 and over | 1 | 2018 | 88759 | 0.02 | Why? |
| Treatment Outcome | 3 | 2019 | 51732 | 0.02 | Why? |
| Parents | 1 | 2020 | 2758 | 0.02 | Why? |
| Interferon-gamma | 1 | 2017 | 2711 | 0.02 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2017 | 2483 | 0.02 | Why? |
| Monitoring, Physiologic | 1 | 2017 | 1956 | 0.02 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.02 | Why? |
| Treatment Failure | 1 | 2012 | 2106 | 0.02 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2020 | 1969 | 0.02 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.02 | Why? |
| Dexamethasone | 1 | 2017 | 2055 | 0.02 | Why? |
| Kidney | 1 | 2019 | 3648 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 7868 | 0.02 | Why? |
| Neutrophils | 1 | 2021 | 5476 | 0.02 | Why? |
| Symptom Assessment | 1 | 2017 | 4967 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.02 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.02 | Why? |
| Survival Rate | 1 | 2018 | 9206 | 0.02 | Why? |
| Pediatrics | 1 | 2017 | 2969 | 0.01 | Why? |
| Europe | 1 | 2017 | 12702 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.01 | Why? |
| Specimen Handling | 1 | 2018 | 6190 | 0.01 | Why? |
| Respiratory Tract Infections | 1 | 2020 | 6817 | 0.01 | Why? |
| Immunocompromised Host | 1 | 2015 | 5150 | 0.01 | Why? |
| Age Factors | 1 | 2019 | 21039 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.01 | Why? |
| Critical Illness | 1 | 2019 | 17281 | 0.01 | Why? |
| Prognosis | 1 | 2019 | 32490 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2019 | 15421 | 0.01 | Why? |
| Comorbidity | 1 | 2019 | 34796 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| Lung | 1 | 2020 | 31049 | 0.01 | Why? |
| United States | 1 | 2018 | 46150 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.01 | Why? |